Ministry of Food and Drug Safety

Cosmetics & Beauty Expo Osong Korea 2023 to be held from Oct 17 to 21

Retrieved on: 
Monday, September 4, 2023
Entertainment, Fitness & Nutrition, Events, Concerts, Other Health, Food, Beverage, Other Education, Health, Cosmetics, Retail, Education, Perfume, Ministry of Food and Drug Safety, Multimedia, II, Organization, Connecticut Business Hall of Fame, Ministry, Beauty, Poster, Corporation, LG, Everett Inbody, K-Beauty, Beauty salon, Tourism, Auction, Nightclub, Osong station

Now in its tenth year, the Cosmetics & Beauty Expo Osong Korea 2023 will be held in Osong Bio Valley from October 17th through 21st.

Key Points: 
  • Now in its tenth year, the Cosmetics & Beauty Expo Osong Korea 2023 will be held in Osong Bio Valley from October 17th through 21st.
  • View the full release here: https://www.businesswire.com/news/home/20230823045941/en/
    2023 Cosmetics & Beauty Expo Osong Korea will be held on Oct 17 to 21 (Poster: Osong Bio-Promotion Foundation)
    200 renowned domestic companies including LG H&H and Pion-Tech as well as around 700 buyers from Korea and abroad are going to participate, and more than 100,000 visitors to the expo are expected.
  • The Cosmetics & Beauty Expo Osong Korea 2023 is the dynamic site where K-Beauty is emerging anew, making it the best place to take a glimpse into all of Korea’s leading cosmetic products.
  • The event is held under the slogan of “K-Beauty in the World: Discover It in Osong”, and it has been designed as “beauty unboxing” from the context of enabling the entire world to receive the gift of beauty in Osong.

SK bioscience and Vaxxas Enter Joint Development Agreement for Needle-Free Patch Delivery of Typhoid Vaccine

Retrieved on: 
Thursday, August 24, 2023
MSD, Vaccine, Partnership, Joint, SK, Life, Typhoid fever, Vaccination, Diarrhea, Hilleman Laboratories, Biotechnology, Infection, IVI, Ministry of Food and Drug Safety, International Vaccine Institute, Fever Dream, World Health Organization, MFDS, Constipation, Research, Temperature, Abdominal pain, Science, Ministry, Salmonella enterica subsp. enterica, Risk, Water, Gavi, Nausea, Memorandum of understanding, Bill, Climate, Mortality, WHO, Health, Headache, Bill & Melinda Gates Foundation, Mental health, Safety, Skin, Fatigue, Disease, Pharmaceutical industry, Food, Wellcome, Rickettsia typhi

SK bioscience and Vaxxas have officially entered into a Joint Development Agreement.

Key Points: 
  • SK bioscience and Vaxxas have officially entered into a Joint Development Agreement.
  • This collaboration is set to revolutionize vaccine delivery by developing a novel vaccine-delivery device combination product using Vaxxas' high-density microarray patch (HD-MAP) platform technology with SK bioscience's proprietary typhoid vaccine.
  • Under the agreement, SK bioscience will supply the antigen utilized by its typhoid conjugate vaccine, SKYTyhpoid™ that was jointly developed by SK bioscience and the International Vaccine Institute (IVI).
  • SK bioscience collaborated with Wellcome and the IVI on the development of a trivalent invasive non-typhoidal Salmonellosis vaccine candidate in 2019.

Eisai Files Marketing Authorization Application for Lecanemab as Treatment For Early Alzheimer's Disease in South Korea

Retrieved on: 
Thursday, June 8, 2023
Disease, Alzheimer's disease, Ministry of Food and Drug Safety, BIIB, Lecanemab, MFDS, Brain, The Different Forms of Flowers on Plants of the Same Species, Ministry, Clarity, Eisai, Co-promotion, AD, Neurotoxicity, Pharmaceutical industry, Biogen, Food

This application is the first application for lecanemab in Asia outside of Japan and China.

Key Points: 
  • This application is the first application for lecanemab in Asia outside of Japan and China.
  • As such, lecanemab may have the potential to have an effect on disease pathology and to slow down the progression of the disease.
  • Eisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.
  • Lecanemab, Aducanumab, and Gantenerumab - Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer's Disease.

Lemonex announces approval of IND application for  mRNA-DegradaBALL vaccine, LEM-mR203, phase 1 clinical trial

Retrieved on: 
Wednesday, August 9, 2023
Research, Pharmaceutical, Medical Devices, Hospitals, University, Health Technology, Education, Clinical Trials, Science, COVID-19, Biotechnology, Health, POC, Inc., IPO, Therapy, LEM, International Vaccine Institute, Ministry of Food and Drug Safety, IVI, Clinical trial, Singapore Workplace Safety and Health Conference, MFDS, Myocarditis, Multimedia, Temperature, RNA, Messenger, Small RNA, Ministry, Investigational New Drug, Microsoft, Bill & Melinda Gates Foundation, Seoul National University Hospital, Risk, Anaphylaxis, DDS, WHO, LNP, Transport, API, IND, Conference, NIH, Safety, Pericarditis, Vaccine, KOSDAQ, Food

It is possible to quickly respond to the next pandemic through pre-production, stock storage, and priority supply of DegradaBALL.

Key Points: 
  • It is possible to quickly respond to the next pandemic through pre-production, stock storage, and priority supply of DegradaBALL.
  • (Provided by Lemonex)
    LEM-mR203 is the first mRNA vaccine candidate to which Lemonex's proprietary drug delivery platform technology, DegradaBALL (DegradaBALL-mRNA system), is applied.
  • This clinical trial is for Covid-19, and safety and immunogenicity will be evaluated in healthy adults at Seoul National University Hospital, Korea.
  • The drug delivery technology of DegradaBALL developed by Lemonex may address these issues, suggesting a more advanced DDS technology for mRNA vaccines and therapeutics.

NeuroStar Achieves Milestone Regulatory Clearance in South Korea

Retrieved on: 
Monday, July 17, 2023
Major depressive disorder, Depression, Marketing, TMS, Organization, Ministry of Food and Drug Safety, Quality of life, MFDS, OECD, MDSAP, Sale, Ministry, STIM, MDD, Patient, D-8 Organization for Economic Cooperation, Transcranial magnetic stimulation, Health, Neuronetics, Pharmaceutical industry, Food

This marks the first international market where NeuroStar has obtained marketing authorization for the expanded indication and cutting-edge technologies.

Key Points: 
  • This marks the first international market where NeuroStar has obtained marketing authorization for the expanded indication and cutting-edge technologies.
  • The NeuroStar 3.7 platform standardizes the NeuroStar hardware globally and includes advancements designed to streamline a clinician’s workflow, such as a touchscreen display with a biometric fingerprint reader.
  • South Korea was also reported to have the greatest suicide rate among nations of the Organization of Economic Cooperation and Development (OECD)2.
  • As a market leader in TMS within the South Korean market, NeuroStar aims to fill this unmet need and has partnered with distributor DK Healthcare to expand access to NeuroStar TMS.

OURHOME announces 115 dishes for 2023 World Scout Jamboree

Retrieved on: 
Thursday, June 15, 2023
Honey, Saemangeum, World Scout Jamboree, Allergy, Tteokguk, Food safety, Ministry of Food and Drug Safety, Multimedia, Ministry, TFS, Cooking, Restaurant, Beef, 25th World Scout Jamboree, Transport, Safety, Ham, Fast food, Food

Completion of preference and individual constitutional surveys through the Jamboree-exclusive food material ordering website in advance…Reinforcing safety, promoting efficiency

Key Points: 
  • Completion of preference and individual constitutional surveys through the Jamboree-exclusive food material ordering website in advance…Reinforcing safety, promoting efficiency
    SEOUL, South Korea, June 15, 2023 /PRNewswire/ -- OURHOME, a global food company based in Korea, announced 115 menu items to be provided to the participants of the 2023 25th World Scout Jamboree at Saemangeum (hereinafter Saemangeum Jamboree), which will be held in August.
  • Since April, the team has held evaluation and tasting meetings on the dishes to be served during the event for key officials of the Jamboree.
  • The information on the entire menu for the Saemangeum Jamboree is available on the World Scout Jamboree official website.
  • Ourhome also launched a 'Jamboree food ingredient ordering website' for this event, which posted details of the menu and guidelines on how to order.

BCWorld Healthcare and ReGelTec have entered into an exclusive distribution agreement for HYDRAFIL™ in the South Korean market

Retrieved on: 
Thursday, June 1, 2023
Pharmaceutical, Health, Other Health, Medical Devices, Partnership, Ministry of Food and Drug Safety, Tears, FDA Center for Devices and Radiological Health, MFDS, Trial of the century, Ministry, Degenerative disc disease, Patient, DDD, Pain management, Device, FDA, Safety, Pharmaceutical industry, Food

ReGelTec, Inc. (ReGelTec) announced that it has entered into an agreement with BCWorld Healthcare Co., Ltd. (BCWH) that provides BCWP exclusive rights to distribute the HYDRAFIL™ System for the treatment of Chronic Low Back Pain (CLBP) due to Degenerative Disc Disease (DDD) in the South Korean market.

Key Points: 
  • ReGelTec, Inc. (ReGelTec) announced that it has entered into an agreement with BCWorld Healthcare Co., Ltd. (BCWH) that provides BCWP exclusive rights to distribute the HYDRAFIL™ System for the treatment of Chronic Low Back Pain (CLBP) due to Degenerative Disc Disease (DDD) in the South Korean market.
  • BCWH will also fund a clinical study in South Korea to support regulatory approval from the Ministry of Food and Drug Safety (MFDS) with ReGelTec providing HYDRAFIL™ Systems for the study.
  • The companies have already started planning regulatory strategies for approval and expect the trial to begin in 2024.
  • “We are excited to secure the rights to distribute the HYDRAFIL™ System in South Korea,” said Steve Hong, CEO and President of BCWH.

DxVx appoints Yong Gu Lee as new CEO and Kevin Kwon as the new president

Retrieved on: 
Tuesday, May 16, 2023
Vaccine, Molecular biology, Hanmi, Hanyang University, Broad Institute, RA, Diabetes, Biochemistry, Catholic higher education, Pharming, National university, RXR Realty, Haemophilus influenzae, Korea University, Ministry of Food and Drug Safety, Cancer, Lead, Medicine, Research, Multimedia, MIT, Pierre and Marie Curie University, Veteran, Harvard University, Bangladesh Technical Education Board, Harvard Medical School, Certification, Organization, Ministry, Core Group, CLIA, Acquisition, Cervical cancer, Seoul National University, Institut Pasteur Korea, Growth, FDA, IND, Pharmaceutical industry, Management, Food

SEOUL, South Korea, May 16, 2023 /PRNewswire/ -- DxVx announced on the 16th, the board of directors appointed Yong Gu Lee as the new CEO and Kevin Kwon, the former head of global business division at Hanmi Pharm.Co.,Ltd., as the new president. Drawing on the expertise of sales veterans who have more than 30 years of experience, the company plans to actively reorganize the global sales networks, launch new products and further enhance its capabilities to get global approvals for new drugs.

Key Points: 
  • SEOUL, South Korea, May 16, 2023 /PRNewswire/ -- DxVx announced on the 16th, the board of directors appointed Yong Gu Lee as the new CEO and Kevin Kwon, the former head of global business division at Hanmi Pharm.Co.,Ltd., as the new president.
  • The new CEO, Yong Gu Lee, graduated from Hanyang University.
  • Co., Ltd., managing director of the healthcare business division at Beijing Medi'Care Co., Ltd and vice president of the COREE Group.
  • New president Kevin Kwon will be appointed as a board director from a shareholders' meeting.

LBank Exchange Will List 5MC on April 25, 2023

Retrieved on: 
Monday, April 24, 2023
Extrapyramidal system, Life, Marketing, Ministry of Food and Drug Safety, Colon, Pain, Ministry, Patent, Health, Impact of the COVID-19 pandemic, Cryptocurrency, Food

Road Town, British Virgin Islands--(Newsfile Corp. - April 24, 2023) - LBank Exchange, a global digital asset trading platform, will list 5MC on April 25, 2023.

Key Points: 
  • Road Town, British Virgin Islands--(Newsfile Corp. - April 24, 2023) - LBank Exchange, a global digital asset trading platform, will list 5MC on April 25, 2023.
  • For all users of LBank Exchange, the 5MC/USDT trading pair will be officially available for trading at 7:00 UTC on April 25, 2023.
  • Its native token 5MC will be listed on LBank Exchange at 7:00 UTC on April 25, 2023, to further expand its global reach and help it achieve its vision.
  • In modern times, the world and countries have studied how to remove coprostasis in line with the trend of the times.

INFINITT Healthcare Solutions Plays a Part in HIMSS DIAM Stage 7 Accreditation for First- in -the -World Medical Center

Retrieved on: 
Thursday, April 6, 2023
ENDO, News, Workflow, EMR, EKG, Software, INFINITT Healthcare, Pathology, MFDS, CIS, Research, Endoscopy, HIMSS, Ministry, Healthcare in New Zealand, EEG, Medical Center, Cardiology, Health, Ministry of Food and Drug Safety, Stage 7, Polyp, SMC, Medical imaging, Medical device, Food

PHILLIPSBURG, N.J., April 6, 2023 /PRNewswire-PRWeb/ -- Samsung Medical Center (SMC) is the first healthcare provider in the world to receive Stage 7 of the HIMSS digital imaging adoption model (DIAM) maturity model. A DIAM assesses a healthcare organization's level of digital imaging maturity and provides guidelines for achieving full enterprise imaging.

Key Points: 
  • Samsung Medical Center (SMC) is the first healthcare provider in the world to receive Stage 7 of the HIMSS digital imaging adoption model (DIAM) maturity model.
  • PHILLIPSBURG, N.J., April 6, 2023 /PRNewswire-PRWeb/ -- Samsung Medical Center (SMC) is the first healthcare provider in the world to receive Stage 7 of the HIMSS digital imaging adoption model (DIAM) maturity model.
  • A DIAM assesses a healthcare organization's level of digital imaging maturity and provides guidelines for achieving full enterprise imaging.
  • INFINITT Healthcare Solutions are currently being used at SMC and were demonstrated in clinical settings during the onsite stage 7 validation.